HOBOKEN, N.J., May 11, 2020 /PRNewswire-PRWeb/ -- Dr. Pashos' successful career has spanned academia, consulting and life sciences companies. Most recently, he served as Vice President, Global Evidence Strategy at AbbVie, strengthening the delivery of appropriate HEOR methods and enhancing collaboration among global, regional and affiliate organizations. Previously, he led Takeda's Global Outcomes and Epidemiology Research, where he led a transformation to deliver HEOR strategically and tactically from early development through the life cycle, integrated across R&D, Medical and commercial units.
Chris began his HEOR career at Harvard Medical School, where he managed the acute myocardial infarction Patient Outcomes Research Team (PORT), one of the first PORTs funded by the United States government to improve healthcare quality. After leaving the Harvard faculty in 1995, he founded and led a consultancy at Abt Associates whose clients were most of the world's leading pharmaceutical companies. He continued as vice president after his team was acquired.
Having lived in North America and Europe and worked with organizations from around the world, his global research has appeared in more than 120 medical journal publications; nearly 300 presentations, book chapters, and reports; and input to UNICEF, NIH, the Surgeon General, and others.
"When thinking of who to appoint to the Genesis Research Board, Chris Pashos was the first person to come to mind – not only for his invaluable industry knowledge and global impact, but also his character, integrity and values. We are delighted to welcome him to the Genesis Family," said Mark Hopkins, Co-Founder and Managing Partner with Rallyday.
"I am so pleased to join Steve Arikian, Frank Corvino, and the wonderful Genesis Research family: thought leaders in Real World Evidence generation and true partners with their clients," said Dr. Pashos. "It is wonderful to see their commitment to providing significant value to their Life Sciences Company clients through scientific excellence, novel working relationships and innovative deliverables," he added.
A Charter Member of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Chris served as ISPOR President in 2008-2009. A recipient of the ISPOR Distinguished Service Award, he led the development of and served as a co-editor of Health Care Costs, Quality and Outcomes: ISPOR Book of Terms (which has been translated from English into many other languages).
We are pleased to welcome Chris to our Board of Directors at this important next stage in Genesis Research's evolution," stated Steve Arikian, MD, Co-Founder & Chairman of the Board of Genesis Research. "As a highly respected and seasoned HEOR executive with valuable biopharmaceutical industry experience, we look forward to Chris' expert assistance in supporting our objective to be the world's leading Value Demonstration Company."
About Genesis Research:
Genesis Research is a value demonstration company, powered by Real World Evidence development serving the Life Sciences industry. As a leader in evidence development and communication, Genesis Research supports clients with unique services such as rapid response analytics, outcomes simulation, payer data collaboration and Evidence Life Cycle Management. For more information about Genesis Research, please visit http://www.GenesisRG.com.
About Rallyday Partners:
Rallyday Partners, headquartered in Denver, Colorado, is a private equity firm investing growth capital in founder led companies in the healthcare, education and IT services industries. Genesis Research is a portfolio company of Rallyday Partners. For more information about Rallyday, please visit http://www.rallydaypartners.com.
SOURCE Genesis Research
Share this article